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Abstract
Patients with breast cancer brain metastases historically have a poor prognosis. In this single-institution
cohort study of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer
brain metastases, we found no improvement in survival after brain recurrence over time despite wide adoption
of HER2etargeted therapies. This highlights the importance of continued development of novel brain pene-
trant therapies for patients with HER2epositive metastatic disease to extend survival and improve quality of
life.
Background: Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for
advanced HER2epositive breast cancer, we studied the natural history of patients with HER2epositive breast cancer
brain metastases (BCBM) over time. Patients and Methods: Patients with HER2epositive BCBM identified from a
prospectively maintained database at the University of North Carolina were divided into 3 cohorts by year of BCBM
diagnosis. Cohorts were selected by year of HER2etargeted therapy US Food and Drug Administration approval.
Overall survival (OS), time to first metastasis, time to BCBM, and BCBM survival were estimated by the Kaplan-Meier
method. Associations between OS after BCBM and clinical variables were assessed by Cox proportional hazards
regression models. Results: One hundred twenty-three patients were identified. Median age was 51 years, and 58%
were white and 31% African American. OS from initial breast cancer diagnosis improved over time: 3.6 years (95%
confidence interval [CI], 2.8-6.1) in the 1998-2007 cohort, 6.6 years (95% CI, 4.5-8.6) in the 2008-2012 cohort, and 7.6
years (95% CI, 4.4-9.6) in the 2013-2015 cohort (P ¼ .05). While time from initial diagnosis to first metastasis did not
differ (P ¼ .12), time to BCBM increased over time (2.6 years [95% CI, 1.3-3.5] for 1998-2007; 2.6 years [95% CI, 2.1-
4.3] for 2008-2012, and 3.3 years [95% CI, 2.2-6] for 2013-2015; P ¼ .05). Although OS from BCBM did not signifi-
cantly differ by cohort, patients who received HER2etargeted therapy after BCBM had a prolonged OS (2.1 years
[95% CI, 1.6-2.6] vs. 0.65 years [95% CI, 0.4-1.3]; P ¼ .001). Conclusion: OS from initial breast cancer diagnosis
significantly improved over time for patients with HER2epositive breast cancer who develop BCBM, now exceeding 7
years; survival from BCBM diagnosis may now exceed 2 years.
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Breast Cancer Metastatic to BrainIntroduction
One-third of women with metastatic human epidermal growth
factor receptor 2 (HER2)-positive breast cancer will be diagnosed with
brain metastases (BCBM) during their disease course.1 HER2epositive
breast cancer carried a poor prognosis in the preetargeted therapy
era.2,3 Even after the approval of trastuzumab in the metastatic setting,
overall survival (OS) from diagnosis of BCBM was less than 1.2
years.1,4 Over the past 2 decades, treatment of patients with advanced
HER2epositive breast cancer has evolved significantly as a result of
the approval of several HER2etargeted therapies now incorporated
into routine practice, which have markedly improved the prognosis
of metastatic HER2epositive breast cancer. What is not yet clear is
whether improved HER2edirected therapies have had the same
impact among patients with BCBM. Variability in the chemical
characteristics of the newer HER2etargeted therapies, and thus
differing abilities to penetrate the bloodebrain barrier (BBB) to
either prevent BCBM or control existing metastatic lesions, suggest
that these agents may have a positive impact on the recurrence rates
in the brain and survival of patients with HER2epositive BCBM.
Multiple trials evaluating HER2edirected agents beyond trastu-
zumab have reported on brain outcomes. Although lapatinib with
capecitabine has been shown to delay time to brain progression
compared to trastuzumab in patients with metastatic HER2epositive
disease, there was no difference in incidence of BCBM between the 2
groups.5 Among patients with disease that progressed while receiving
trastuzumab, lapatinib plus capecitabine compared to capecitabine
alone is associated with a reduced risk of brain as the site of first
progression.6 In patients with radiation-naive HER2epositive
BCBM, lapatinib plus capecitabine resulted in a reduction in BCBM
volume from baseline in 84% of patients, suggesting it may be a
reasonable first-line treatment.7 Moving beyond lapatinib, an
exploratory analysis of patients from the CLEOPATRA trial reported
that in those with HER2epositive metastatic breast cancer treated
with trastuzumab and docetaxel, while the addition of pertuzumab
did not change the incidence of the brain as the first site of disease
recurrence, it did delay the onset of and trend toward an increased OS
after diagnosis of BCBM.8 While ado-trastuzumab emtansine
(TDM-1) was initially thought to have limitations to crossing the
BBB similar to trastuzumab, several reports illustrate intracranial re-
sponses in the setting of HER2epositive BCBM.9-12 The EMILIA
study comparing TDM-1 with lapatinib plus capecitabine in patients
with advanced HER2epositive disease pretreated with trastuzumab
found that while the proportion of patients with brain progression
was the same in both groups, in patients with preexisting BCBM,
TDM-1 conferred a prolonged OS.10 The TH3RESA study found
that in patients with advanced HER2epositive breast cancer pre-
treated with 2 or more HER2etargeted agents, those in the TDM-1
group, including those with previously treated BCBM, had a longer
progression-free survival than the physician’s-choice group.12
These emerging data indicate that patients with HER2epositive
metastatic disease are benefiting from therapeutic advances. In light
of these advances, however, a collective analysis of BCBM outcomes
in the modern era has yet to be performed. Thus, we performed a
single-institution cohort study to examine the magnitude of this
benefit in patients with BCBM during the era of modern
HER2etargeting.Clinical Breast Cancer February 2018Methods
Patients included in this study had metastatic HER2epositive
breast cancer with BCBM at any point during their disease course.
Informed consent was not obtained from participants included in
the study because a waiver of consent and waiver of Health Insur-
ance Portability and Accountability Act authorization were both
approved by the University of North Carolina (UNC) Biomedical
institutional review board on May 9, 2015.
Relevant data for this population were retrieved using 2 clinical
databases at UNC. The UNC Breast Cancer Metastatic Database
contains demographic, clinical, and treatment data on all metastatic
breast cancer patients treated at the UNCeChapel Hill Cancer
Hospital from 2012 to the present. A second database collected
information on breast cancer patients treated at UNC between 1991
and 2012. Within the databases, HER2 positivity was defined as
either positive by immunohistochemistry or amplified by fluores-
cence in-situ hybridization. Tumors were hormone receptor positive
if estrogen receptor, progesterone receptor, or both were positive,
and hormone receptor negative if both estrogen receptor and pro-
gesterone receptor were negative.
A total of 123 patients were identified from both databases,
yielding the cohort for this study. Patient follow-up data were
available through May 2015, with a median follow-up of 1.75 years
(range, 0.1-12 years) from BCBM diagnosis. UNC institutional
review board approval was obtained to conduct this retrospective
analysis. Of note, UNC has a dedicated BCBM clinic and research
program, initiated on August 1, 2012.
Statistical Analysis
Patients were divided into 3 cohorts for analysis as defined by
year of BCBM diagnosis. Cohort time intervals were selected on the
basis of year of HER2etargeted therapy US Food and Drug
Administration (FDA) approval: 1998-2007 for trastuzumab,
2008-2012 for lapatinib, and 2013-2015 for pertuzumab and
TDM-1. The Kaplan-Meier method and log-rank test were used to
estimate and compare OS from initial breast cancer diagnosis, time
from initial breast cancer diagnosis to first metastatic diagnosis, time
from initial breast cancer diagnosis to BCBM, time from first
metastatic diagnosis to BCBM, and OS from BCBM diagnosis.
Subsequent pairwise log-rank tests were performed if the overall test
was significant. Univariable and multivariable Cox proportional
hazards regression modeling was used to evaluate associations of
clinical variables with OS from BCBM. All analyses were conducted
by SAS 9.4 statistical software (SAS Institute, Cary, NC).
Results
Demographics and Treatment Pattern of Patient
Population
Demographic and clinical characteristics for patients in each
cohort are listed in Table 1. Median age at breast cancer diagnosis
was 51 years. Fifty-eight percent of the study population was white
and 31% African American. Of the 123 HER2epositive BCBM
patients, 30% were diagnosed with BCBM between 1998 and
2007, 37% between 2008 and 2012, and 33% between 2013 and
2015. Treatment received for early-stage I to III disease and for
nonebrain metastatic disease is provided in Table 1. Receipt of




No. of patients 123 37 (30%) 45 (37%) 41 (33%) —
Age at Diagnosis of Brain
Metastasis
.13
Median (range), y 51 (32-72) 47 (32-68) 55 (33-72) 52 (36-71)
50 y 53 (42%) 21 (57%) 16 (36%) 16 (39%)
>50 y 70 (57%) 16 (43%) 29 (64%) 25 (61%)
Race .91
White 72 (58%) 23 (62%) 26 (62%) 23 (57%)
African American 38 (31%) 12 (32%) 12 (29%) 14 (35%)
Asian 3 (2%) 0 (0%) 2 (5%) 1 (2%)
Other 6 (5%) 2 (5%) 2 (5%) 2 (5%)
AJCC Stage at Diagnosis .77
0 3 (2%) 0 (0%) 2 (5%) 1 (2%)
I 10 (8%) 4 (11%) 4 (10%) 2 (5%)
II 24 (19%) 7 (19%) 6 (15%) 11 (27%)
III 42 (34%) 12 (32%) 15 (37%) 15 (37%)
IV 40 (32%) 14 (38%) 14 (34%) 12 (29%)
IHC Subtype .54
HER2/HR negative 68 (55%) 19 (53%) 28 (62%) 21 (51%)
HER2/HR positive 54 (44%) 17 (42%) 17 (38%) 20 (49%)
Breast Surgery Received .15
Mastectomy 77 (63%) 27 (73%) 28 (62%) 22 (54%)
Lumpectomy 20 (16%) 2 (5%) 9 (20%) 9 (22%)
Biopsy only 16 (13%) 1 (3%) 5 (11%) 10 (24%)
None performed 10 (8%) 7 (19%) 3 (7%) 0 (0%)
Therapy for Early Stage I to III
Disease (n [ 79, 64%)
Chemotherapy 65 (82%) 19 (83%) 20 (74%) 26 (90%) .31
Endocrine therapy 35 (46%) 10 (44%) 12 (50%) 13 (45%) .89
HER2etargeted therapy 40 (54%) 7 (32%) 13 (57%) 20 (69%) .03
Radiotherapy 49 (71%) 14 (78%) 16 (73%) 19 (66%) .65
Presence of brain metastasis at
first metastatic diagnosis
36 (29%) 9 (24%) 17 (38%) 10 (24%) .29
Therapy for Nonbrain Metastatic
Disease (n [ 87, 71%)
Chemotherapy 71 (82%) 26 (93%) 18 (64%) 27 (87%) .01
Endocrine therapy 35 (40%) 7 (25%) 16 (57%) 12 (39%) .05
HER2etargeted therapy 72 (83%) 22 (79%) 24 (86%) 26 (84%) .76
Trastuzumab 72 (100%) 22 (100%) 24 (100%) 26 (100%) .99
Lapatinib 21 (29%) 2 (95%) 10 (42%) 9 (35%) .04
Pertuzumab 14 (19%) 0 (0%) 0 (0%) 14 (54%) <.01
TDM-1 3 (4%) 0 (0%) 0 (0%) 3 (12%) .06
Abbreviations: AJCC ¼ American Joint Committee on Cancer; HER2 ¼ human epidermal growth factor receptor 2; HR ¼ hormone receptor; IHC ¼ immunohistochemical; TDM-1 ¼ ado-trastuzumab
emtansine.
Louisa A. Mounsey et alHER2etargeted therapy for early stage I to III disease increased
over time: 32% of the 1998-2007 cohort, 57% of the 2008-2012
cohort, and 69% of the 2012-2015 cohort (P ¼ .03).
Table 2 lists the treatment received for BCBM. Of these thera-
pies, radiotherapy was the first therapeutic intervention after BCBM
diagnosis in most patients across all time cohorts (79% 1998-2007,72% 2008-2012, and 63% 2013-2015), followed by surgery
(7% 1998-2007, 17% 2008-2012, and 24% 2013-2015), chemo-
therapy, and HER2etargeted therapy (P ¼ .10). A similar pro-
portion (approximately 80%) of patients received trastuzumab
across all cohorts, while lapatinib use after BCBM varied over time
(48% 1998-2007, 79% 2008-2012, and 42% 2013-2015)Clinical Breast Cancer February 2018 - 31




No. of Brain Metastases at Initial
BCBM Diagnosis
<.0001
1 40 14 (40%) 16 (39%) 10 (24%)
2 20 9 (26%) 7 (17%) 4 (10%)
3 24 12 (34%) 10 (24%) 2 (5%)
4 4 0 (0%) 1 (2%) 3 (7%)
5þ 29 0 (0%) 7 (17%) 22 (54%)
Therapy After BCBM Diagnosis .65
Chemotherapy 76 24 (69%) 28 (65%) 24 (59%)
Lines of Chemotherapy .21
1 line 32 10 (29%) 10 (23%) 12 (29%)
2 lines 23 6 (17%) 9 (21%) 8 (19%)
3 lines 6 5 (14%) 1 (2%) 0 (0%)
4þ lines 15 3 (9%) 8 (19%) 4 (10%)
Endocrine therapy 20 7 (20%) 10 (24%) 3 (7%) .11
HER2etargeted therapy 76 23 (62%) 34 (76%) 19 (46%) .02
Trastuzumab 60 19 (19/23, 83%) 26 (26/34, 76%) 15 (15/19, 79%) .86
Lapatinib 46 11 (11/23, 48%) 27 (27/34, 79%) 8 (9/19, 42%) .009
Pertuzumab 11 0 (0%) 2 (2/34, 6%) 9 (9/19, 47%) <.0001
TDM-1 14 0 (0%) 4 (4/24, 12%) 10 (10/19, 53%) <.0001
Radiation .17
None 17 8 (22%) 5 (11%) 4 (10%)
WBRT alone 64 23 (62%) 21 (47%) 20 (49%)
SRS alone 22 3 (8%) 9 (20%) 10 (24%)
Both 20 3 (8%) 10 (22%) 7 (17%)
Surgical intervention 33 9 (24%) 13 (29%) 11 (27%) .90
Abbreviations: BCBM ¼ breast cancer brain metastasis; HER2 ¼ human epidermal growth factor receptor 2; SRS ¼ stereotactic radiosurgery; TDM-1 ¼ ado-trastuzumab emtansine; WBRT ¼ whole
brain radiotherapy.
Figure 1 Overall Survival From Initial Breast Cancer Diagnosis
by Year of Diagnosis
Breast Cancer Metastatic to Brain
32 -(P ¼ .009). More patients received pertuzumab (P < .0001) and
TDM-1 (P < .0001) over time.
Survival From Initial Breast Cancer Diagnosis
Ninety-two patients (75%) are deceased. Median OS from initial
breast cancer diagnosis for the entire cohort was 6.05 years
(95% confidence interval [CI], 4.37-7.03) and improved over time:
3.56 years for 1998-2007 (95% CI, 2.78-6.05), 6.64 years for
2008-2012 (95% CI, 4.5-8.58), and 7.55 years for 2013-2015
(95% CI, 4.37-9.63) (P ¼ .05) (Figure 1).
Time to First Metastatic Diagnosis and Time to Brain
Recurrence
Median time from initial breast cancer diagnosis to first meta-
static diagnosis was 1.52 years (95% CI, 1.07-2.03), median time
from first metastatic diagnosis to BCBM was 1.11 years (95% CI,
0.76-1.38), and median time from initial breast cancer diagnosis to
BCBM was 2.88 years (95% CI, 2.22-3.42). Time from initial
breast cancer diagnosis to first metastatic diagnosis numerically
increased over time but was not statistically significant (P ¼ .12)
(Figure 2). Time from first metastatic diagnosis to BCBM diagnosis
also did not significantly change over time (P ¼ .13) (Figure 3).Clinical Breast Cancer February 2018
Figure 2 Time From Initial Breast Cancer Diagnosis to First
Metastatic Diagnosis by Year of Diagnosis
Figure 4 Time to Breast Cancer Brain Metastasis Diagnosis
From Initial Breast Cancer Diagnosis by Year of
Diagnosis
Louisa A. Mounsey et alTime from initial breast cancer diagnosis to BCBM diagnosis,
however, increased over time, with a median time to brain recur-
rence of 2.63 years for 1998-2007 (95% CI, 1.34-3.5), 2.61 years
for 2008-2012 (95% CI, 2.11-4.31), and 3.32 years for 2013-2015
(95% CI, 2.22-6.01) (P ¼ .05) (Figure 4).
Brain MetastasiseSpecific Survival
OS from BCBM diagnosis was 1.51 years (95% CI, 1.24-2.05)
for the entire cohort and was not significantly different over time (P ¼
.24) (Figure 5). Interestingly, those who received HER2etargeted
therapy (62%) after BCBM diagnosis had a median OS of 2.11
years (95% CI, 1.55-2.60) compared to 0.65 years (95% CI,
0.38-1.25) in those who did not receive HER-2etargeted treatment
(P ¼ .001) (Figure 6).Figure 3 Time From First Metastatic Diagnosis to Breast
Cancer Brain Metastasis Diagnosis by Year of
DiagnosisDemographic and clinical characteristics of patients who received
HER2etargeted therapy for BCBM compared to those who did not
are listed in Table 3. A higher proportion of white subjects received
HER2etargeted therapies compared to African American subjects
(69% vs. 45%, P ¼ .03). A higher proportion of patients in earlier
cohorts received HER2etargeted therapies after BCBM than in the
recent cohort (62% for 1998-2007, 76% for 2008-2012, and 46%
for 2013-2015, P ¼ .02).
Univariable and Multivariable Cox Regression Analysis
Univariable analysis shows that receipt of HER2etargeted therapy
after BCBM diagnosis was the only demographic, clinical, and
treatment variable significantly associated with OS from BCBM
diagnosis (hazard ratio 0.51, 95%CI 0.33-0.78) (Table 4). Given thisFigure 5 Overall Survival After Breast Cancer Brain Metastasis
Diagnosis by Year of Diagnosis
Clinical Breast Cancer February 2018 - 33
Table 3 Demographic and Clinical Characteristics of
Patients Who Received HER2eTargeted Therapy After













50 y 34 (64%) 19 (36%) .64
>50 y 42 (60%) 28 (40%)
Race
African American 17 (45%) 21 (55%) .03
White 50 (69%) 22 (31%)
Asian 1 (33%) 2 (67%)
Other 5 (83%) 1 (17%)
Stage .61
0 2 (67%) 1 (33%)
I 5 (50%) 5 (50%)
II 12 (50%) 12 (50%)
III 27 (64%) 15 (36%)
IV 27 (67%) 13 (32%)
HER2/HRþ 39 (57%) 29 (43%) .21




1999-2007 23 (62%) 14 (38%)
2008-2012 34 (76%) 11 (24%)




1-3 52 (62%) 32 (38%) .67
>3 19 (58%) 14 (42%)
Abbreviations: BCBM ¼ breast cancer brain metastasis; HER2 ¼ human epidermal growth
factor receptor 2; HR ¼ hormone receptor.
Figure 6 Overall Survival After Breast Cancer Brain Metastasis
Diagnosis by Receipt of HER2eTargeted Therapy
Breast Cancer Metastatic to Brain
34 -result, the finding that receipt of HER2etargeted therapy differs by
both race and cohort, and sample size limitations, a multivariable
model was fit to investigate if this relationship held after controlling
for race and year of BCBM diagnosis. Receipt of HER2etargeted
therapy after BCBM diagnosis remained significantly associated with
longer OS from BCBM diagnosis (Table 5).
Discussion
The purpose of this analysis was to reexamine the natural history
of HER2epositive metastatic breast cancer with brain progression
in the era of newer HER2etargeted therapies. Among a cohort of
123 patients with HER2epositive BCBM treated at UNCeChapel
Hill, there has been no significant change in survival after a diag-
nosis of BCBM over time. However, the median time to diagnosis
of BCBM from initial breast cancer diagnosis appears to have
increased by 9 months in the most recent era, 2013-2015, during
which patients with HER2epositive disease have the benefit of
multiple targeted agents. We attribute this increased time to BCBM
diagnosis to both a prolonged time from initial breast cancer diag-
nosis to first metastatic diagnosis and from first metastatic diagnosis
to BCBM diagnosis. Collectively, this leads to a delayed diagnosis of
BCBM over time. These data provide a new historical control and
framework for the manner in which we design novel clinical trials
for this patient population, both in the prevention and active-
therapy settings.
The advent of new HER2etargeted therapies contributes to a
longer time from initial breast cancer diagnosis to BCBM diagnosis.9-12
We demonstrated that patients exposed to any HER2etargeted
treatment after their diagnosis of BCBM experienced a significantly
longer OS than those not so exposed. Fewer patients in the 2013-
2015 cohort received HER2etargeted therapy after BCBM
compared to the 2 earlier cohorts. Because our survival analyses
show that we are extending the time from initial diagnosis to
BCBM diagnosis, we assert that in recent years, patients are
diagnosed with BCBM later with more aggressive systemic diseaseClinical Breast Cancer February 2018and thus do not have the opportunity to benefit from
HER2etargeted therapies. Another contributor is that many have
already received newer HER2etargeted therapies before intracra-
nial recurrence, as seen in this analysis, with over half of patients
diagnosed with BCBM between 2013 and 2015 receiving pertu-
zumab and 12% receiving TDM-1 for nonebrain metastatic
disease. Furthermore, over 80% of patients received
HER2etargeted therapy for nonebrain metastatic disease, which
was not significant across time cohorts. Thus, once brain metas-
tases occurred, the majority of available antieHER2etargeted
therapies had already been prescribed.
A greater proportion of white subjects in our cohort received
HER2etargeted therapy compared to African American subjects
after BCBM diagnosis. This aligns with previous studies demon-
strating racial disparity in HER2etargeted therapy throughout the
disease course.13,14 Notably, multivariable modeling did not indi-
cate race to be significantly related to mortality after BCBM
Table 5 Multivariable Cox Regression Models for Mortality
After HER2ePositive BCBM Diagnosis












Abbreviations: BCBM ¼ breast cancer brain metastasis; CI ¼ confidence interval; HER2 ¼
human epidermal growth factor receptor 2; OR ¼ odds ratio.
Table 4 Univariable Cox Regression Models for Mortality After
HER2ePositive Breast Cancer Brain Metastasis
Diagnosis
Variable HR (95% CI)
Age at BCBM Diagnosis 1.00 (0.99-1.03)
50 y 1.00











HER2/HR negative 0.895 (.59-1.36)












Abbreviations: BCBM ¼ breast cancer brain metastasis; CI ¼ confidence interval;
HER2 ¼ human epidermal growth factor receptor 2; HR ¼ hormone receptor;
IHC ¼ immunohistochemical; OR ¼ odds ratio.
Louisa A. Mounsey et aldiagnosis, with receipt of HER2etargeted therapy being the only
significant variable. This aligns with a previous study indicating no
race-specific differences in survival after BCBM diagnosis.4
Despite the approval of 3 newHER2etargeted therapies during the
course of this study, there is room for improvement in the survival of
patients after a diagnosis of HER2epositive BCBM. This underscores
the potential importance of new brain-penetrant therapies: COX2-
MMP1/CCL7 has been identified as a targetable pathway for
BCBM.15 TPI-287, a novel brain permeable taxane, is in phase 2
clinical trials (NCT01332630).16,17 Several clinical trials evaluating
novel brain-permeable agents are ongoing: 4-demethyl-4-
cholesteryloxycarbonylpenclome chemotherapy (NCT02038218)18;
eribulin mesylate, a microtubule inhibitor (NCT02581839)19; cabo-
zantinib, a tyrosine kinase andVEGFR2 inhibitor (NCT02260531)20;
and abemaciclib, a cdk4/6 inhibitor (NCT02308020).21 Efficacy of
ANG1005, a novel formulation of paclitaxel bound to angio-pep that
binds the low-density lipoprotein receptorerelated protein 1 receptor
on the BBB, is being investigated for recurrent brain metastases
(NCT02048059).22 Two small-molecule HER2etargeted agents are
being evaluated: neratinib, an irreversible inhibitor of erbB1, HER2,
and erbB4 (NCT01494662); and KD019, a tyrosine kinase inhibi-
tor of HER2, EGFR, and VEGFR2/KDR (NCT02154529).23-25 Aphase 2 randomized trial of neratinibwithpaclitaxel versus trastuzumab
with paclitaxel showed no difference in progression-free survival, but
the combination with neratinib may delay the onset and reduce the
frequency of central nervous system progression.24 Other clinical trials
are evaluating combinations of brain-permeable FDA-approved ther-
apies: lapatinib, everolimus, and capecitabine (NCT01783756)26;
everolimus with trastuzumab and vinorelbine (NCT01305941)27;
and lapatinib with cabazitaxel, a brain-permeable taxane
(NCT01934894).28 We remain hopeful that these strategies will
translate into improvements in the survival of patients after a diagnosis
of HER2epositive BCBM.
While the number of brain metastases at initial BCBM diagnosis
significantly increased over time, this did not influence survival after
BCBM recurrence. We attribute this increased number of brain
lesions at BCBM diagnosis to improvements in magnetic resonance
imaging detection and resolution of smaller lesions that may not
have been detected on older imaging platforms.
Our multivariable model shows receipt of HER2etargeted
therapy after BCBM was significantly associated with prolonged OS
after BCBM, even after controlling for race and time cohort. These
results differ from a previous model, the BreasteGraded Prognostic
Assessment of Sperduto et al,29 intended to identify prognostic
factors associated with survival in patients with BCBM, due to our
focus on HER2epositive disease and the development of this prior
model before wide utilization of novel HER2etargeted therapies.
We hypothesize that as the therapeutic landscape of
HER2epositive breast cancer evolves, and as more data are
uncovered regarding the biology of brain metastases, tools such as
the BreasteGraded Prognostic Assessment will likely expand and
become more precise.
We recognize several limitations in our analysis. First, the
UNCeChapel Hill Cancer Hospital is a referral center with a
dedicated BCBM clinic, which may attract patients with systemi-
cally different diseases. Second, a small number of patients received
pertuzumab and TDM-1 due to their relatively recent FDA
approval in 2012 and 2013, respectively. Thirty-one patients (25%)
were still alive at the time of data extraction, and thus over time weClinical Breast Cancer February 2018 - 35
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36 -expect that a higher proportion of patients will be exposed to these
newer therapies as results from ongoing trials comparing efficacy of
existing HER2etargeted agents become available. Third, we do not
have data on the presence of extracranial disease at BCBM diagnosis
for the cohorts before 2012. In the univariate analysis, presence of
extracranial disease at BCBM diagnosis was not significant over
time, which is likely explained by the paucity of data. Finally, the
retrospective nature of this analysis does not allow causation to be
drawn between the natural history of the disease and the specific
therapy received.
In summary, OS of patients with HER2epositive BCBM has
increased, largely as a result of prolonged time between initial breast
cancer diagnosis and diagnosis of BCBM over the decades. The lack
of improvement in survival once BCBM are diagnosed support the
continued development of novel brain-penetrant therapies for pa-
tients with HER2epositive metastatic disease to extend survival and
improve quality of life.
Clinical Practice Points
 One-third of women with metastatic HER2epositive breast
cancer will be diagnosed with BCBM during their disease course.
After approval of trastuzumab in the metastatic setting, OS from
diagnosis of BCBM was less than 1.2 years. The effect of FDA
approval of additional HER2etargeted agents including lapati-
nib, pertuzumab, and TDM-1 on the natural history of disease
in these patients is less clear.
 In this cohort of patients with HER2epositive BCBM, while the
OS from initial breast cancer diagnosis has increased over time,
survival after diagnosis of brain recurrence has not improved.
However, patients who were exposed to any HER2etargeted
agent after BCBM diagnosis had a longer survival after BCBM
diagnosis than those not so exposed.
 These data provide a new historical control and framework for
the manner in which we design novel clinical trials for this pa-
tient population, both in the prevention and active-therapy set-
tings. These data should encourage clinicians to utilize the
available HER2etargeted agents when clinically indicated in
patients with HER2epositive brain metastases.Acknowledgments
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